journal
Journals Alimentary Pharmacology & Ther...

Alimentary Pharmacology & Therapeutics

https://read.qxmd.com/read/38709121/editorial-can-dietary-gluten-restriction-improve-hepatic-steatosis-authors-reply
#21
EDITORIAL
Angelo Armandi, Detlef Schuppan, Jörn M Schattenberg
No abstract text is available yet for this article.
May 6, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38709108/letter-the-enigma-of-angiotensin-receptor-blocker-associated-enteropathy-authors-reply
#22
LETTER
Annalisa Schiepatti, Stiliano Maimaris, Federico Biagi, David S Sanders
No abstract text is available yet for this article.
May 6, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38695095/real-life-effectiveness-of-sofosbuvir-velpatasvir-voxilaprevir-in-hepatitis-c-patients-previously-treated-with-sofosbuvir-velpatasvir-or-glecaprevir-pibrentasvir
#23
JOURNAL ARTICLE
Juan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, Adolfo Gallego Moya, Isabel Conde Amiel, Ana Arencibia, Moises Diago, Javier García-Samaniego, Jose Castellote, Susana Llerena, Elisa Rodríguez-Seguel, Beatriz Mateos, Manuel Rodríguez, Jose Miguel Rosales Zabal, Inmaculada Fernández, Jose Luis Calleja, Rosa María Morillas, Silvia Montoliu, Raul J Andrade, Ester Badia Aranda, Manuel Hernández-Guerra, Carlota Jimeno Maté, Jesús M González-Santiago, Beatriz de Cuenca, Vanesa Bernal-Monterde, Manuel Delgado, Juan Turnes, Sabela Lens, María Buti
BACKGROUND: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). METHODS: Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022...
May 2, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38693757/updates-in-characteristics-and-survival-rates-of-cirrhosis-in-a-nationwide-cohort-of-real-world-u-s-patients-2003-2021
#24
JOURNAL ARTICLE
Sally Tran, Biyao Zou, KeeSeok Lee, Leslie Kam, YeeHui Yeo, Linda Henry, Ramsey Cheung, Mindie H Nguyen
BACKGROUND: Adverse outcomes of cirrhosis remain a top priority. AIMS: We examined the distribution of cirrhosis causes, HCC incidence and mortality and related changes over time in a nationwide U.S. METHODS: A retrospective study of a national sample of commercially insured patients with cirrhosis from Optum's de-identified Clinformatics® Data Mart Database (CDM). RESULTS: A total of 628,743 cirrhosis cases were identified with 45% having NAFLD, 19...
May 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38693747/the-use-of-opioids-nine-months-after-surgery-for-crohn-s-disease-a-nationwide-cohort-study
#25
JOURNAL ARTICLE
Bente Mertz Nørgård, Caroline Thingholm Thorarinsson, Floor Dijkstra Zegers, Jens Kjeldsen, Rahul S Dalal, Ken Lund, Torben Knudsen
BACKGROUND: The risk of chronic opioid use after surgery for Crohn's disease (CD) is not known. AIM: The aim of this study is to examine the chronic opioid use after surgery according to age at time of surgery and to opioid use prior to surgery. METHODS: This nationwide cohort study included patients with a first surgery for CD (January 1, 1996 through 2021). We examined prescribed opioids 9 months after surgery and estimated adjusted odds ratios (OR) for chronic opioid use in elderly (≥60 years), adults (≥40 and <60 years), and young adults (≥18 and <40 years) according to opioid use prior to surgery...
May 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38693718/the-deep-abdominal-ultrasound-transducer-dax-increases-the-success-rate-and-diagnostic-accuracy-of-shear-wave-elastography-for-liver-fibrosis-assessment-in-patients-with-obesity-a-prospective-biopsy-controlled-study
#26
JOURNAL ARTICLE
David J M Bauer, Larissa Nixdorf, Nina Dominik, Michael Schwarz, Benedikt S Hofer, Lukas Hartl, Georg Semmler, Mathias Jachs, Benedikt Simbrunner, Julia Jedamzik, Behrang Mozayani, Lisa Gensthaler, Daniel Moritz Felsenreich, Michael Trauner, Felix Benedikt Langer, Mattias Mandorfer, Gerhard Prager, Thomas Reiberger
BACKGROUND: Obesity impacts the diagnostic accuracy of shear wave elastography (SWE). A deep abdominal ultrasound transducer (DAX) capable of point (pSWE) and two-dimensional (2D)-SWE has recently been introduced to address this issue. METHODS: We performed a prospective study in a cohort of mostly patients with obesity undergoing liver biopsy with a high prevalence of metabolic dysfunction-associate steatotic liver disease (MASLD). Liver stiffness measurement (LSM) was measured using vibration-controlled transient elastography (VCTE), as well as pSWE and 2D SWE on the standard (5C1) and the DAX transducers...
May 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38693712/review-article-evaluation-and-care-of-the-critically-ill-patient-with-cirrhosis
#27
REVIEW
Iva Kosuta, Madhumita Premkumar, K Rajender Reddy
BACKGROUND: The increase in prevalence of liver disease globally will lead to a substantial incremental burden on intensive care requirements. While liver transplantation offers a potential life-saving intervention, not all patients are eligible due to limitations such as organ availability, resource constraints, ongoing sepsis or multiple organ failures. Consequently, the focus of critical care of patients with advanced and decompensated cirrhosis turns to liver-centric intensive care protocols, to mitigate the high mortality in such patients...
May 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38690746/longitudinal-outcomes-of-obeticholic-acid-therapy-in-ursodiol-nonresponsive-primary-biliary-cholangitis-stratifying-the-impact-of-add-on-fibrates-in-real-world-practice
#28
JOURNAL ARTICLE
E Gómez, J L Montero, E Molina, L García-Buey, M Casado, J Fuentes, M A Simón, A Díaz-González, F Jorquera, R M Morillas, J Presa, M Berenguer, M I Conde, A Olveira, G Macedo, I Garrido, M Hernández-Guerra, I Olivas, S Rodríguez-Taje, M Londoño, J M Sousa, J Ampuero, E Romero-González, Sh González-Padilla, D Escudero-García, A Carvalho, A Santos, M L Gutiérrez, E Pérez-Fernández, L Aburruza, J Uriz, D Gomes, L Santos, J Martínez-González, A Albillos, C M Fernández-Rodríguez
BACKGROUND: Suboptimal response to ursodeoxycholic acid occurs in 40% of primary biliary cholangitis (PBC) patients, affecting survival. Achieving a deep response (normalisation of alkaline phosphatase [ALP] and bilirubin ≤0.6 upper limit of normal) improves survival. Yet, the long-term effectiveness of second-line treatments remains uncertain. AIMS: To evaluate the long-term effectiveness of obeticholic acid (OCA) ± fibrates. Focusing on biochemical response (ALP ≤1...
May 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38664887/letter-association-of-persistently-high-hbsag-levels-during-hbeag-seropositive-stage-and-hepatocellular-carcinoma-risk-in-chronic-hepatitis-b-patients-authors-reply
#29
LETTER
Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
No abstract text is available yet for this article.
April 25, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38664876/long-term-clinical-outcomes-in-steatotic-liver-disease-and-incidence-of-liver-related-events-cardiovascular-events-and-all-cause-mortality
#30
JOURNAL ARTICLE
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Masayuki Kurosaki, Rohit Loomba, Namiki Izumi
BACKGROUND: A multi-society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic-dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol-associated liver disease (ALD). However, the risk of liver-related events, major adverse cardiovascular events (MACE) and all-cause mortality among various sub-groups is unknown. AIMS: To evaluate the risk of liver-related events, MACE and death among patients with SLD...
April 25, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38654428/dietary-factors-and-patterns-in-relation-to-risk-of-later-onset-ulcerative-colitis-in-chinese-a-prospective-study-of-0-5%C3%A2-million-people
#31
JOURNAL ARTICLE
Shuyao Song, Zhiyu Wu, Jun Lv, Canqing Yu, Dianjianyi Sun, Pei Pei, Lang Pan, Ling Yang, Yiping Chen, Huaidong Du, Lingli Chen, Dan Schmidt, Daniel Avery, Liping Duan, Junshi Chen, Zhengming Chen, Liming Li, Yuanjie Pang
BACKGROUND: There is limited evidence on the associations of dietary factors and patterns with risk of later-onset ulcerative colitis (UC) in Chinese adults. AIMS: To investigate the associations of dietary factors and patterns with risk of later-onset UC in Chinese. METHODS: The prospective China Kadoorie Biobank cohort study recruited 512,726 participants aged 30-79. Dietary habits were assessed using food frequency questionnaires. Dietary patterns were derived by factor analysis with a principal component method...
April 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38651779/recent-steroid-use-and-the-relapse-risk-in-ulcerative-colitis-patients-with-endoscopic-healing
#32
JOURNAL ARTICLE
Tomohiro Fukuda, Hajime Yamazaki, Yusuke Miyatani, Tsunaki Sawada, Naoki Shibuya, Yuka Fukuo, Hiroki Kiyohara, Hiromu Morikubo, Keiichi Tominaga, Kazuki Kakimoto, Takayuki Imai, Katsuki Yaguchi, Shojiro Yamamoto, Katsuyoshi Ando, Nobuaki Nishimata, Takeo Yoshihara, Akira Andoh, Toshifumi Hibi, Katsuyoshi Matsuoka
BACKGROUND: Endoscopic healing (EH) is a therapeutic target in ulcerative colitis (UC). However, even patients who have achieved EH relapse frequently. AIMS: To investigate the association between recent steroid use and relapse risk in UC patients with EH. METHODS: This multi-centre cohort study included 1212 UC patients with confirmed EH (Mayo endoscopic subscore ≤1). We excluded patients with current systemic steroid use or history of advanced therapy...
April 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38651771/meta-analysis-persistence-of-advanced-therapies-in-the-treatment-of-inflammatory-bowel-disease
#33
REVIEW
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W Leong
BACKGROUND: The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real-world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial year of treatment. AIM: To provide real-world evidence on treatment effectiveness, tolerability and preferences of physicians and patients regarding various advanced therapies for IBD...
April 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38651312/hepatic-inflammation-and-fibrosis-are-profiles-related-to-mid-term-mortality-in-biopsy-proven-masld-a-multicenter-study-in-japan
#34
JOURNAL ARTICLE
Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Hirokazu Takahashi, Miwa Kawanaka, Yoshio Sumida, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Shinichiro Ueda, Shinichi Aishima, Atsushi Nakajima, Takeshi Okanoue
AIMS: A multi-stakeholder consensus has proposed MASLD (metabolic dysfunction-associated steatotic liver disease). We aimed to investigate the pathological findings related to the mid-term mortality of patients with biopsy-proven MASLD in Japan. METHODS: We enrolled 1349 patients with biopsy-proven MASLD. The observational period was 8010 person years. We evaluated independent factors associated with mortality in patients with MASLD by Cox regression analysis. We also investigated pathological profiles related to mortality in patients with MASLD using data-mining analysis...
April 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38650481/magnetic-resonance-enterography-findings-46%C3%A2-weeks-after-initiation-of-biological-therapy-predict-long-term-adverse-outcomes-in-crohn-s-disease
#35
JOURNAL ARTICLE
Agnès Fernández-Clotet, Ingrid Ordás, Maria Carme Masamunt, Berta Caballol, Sonia Rodríguez, Marta Gallego, Rebeca Barastegui, Anny Carolina Saavedra, Julián Panés, Elena Ricart, Jordi Rimola
BACKGROUND AND AIMS: Magnetic resonance enterography (MRE) depicts transmural changes in response to biological treatment for Crohn's disease (CD); however, the long-term prognostic significance of these findings is unknown. The primary objective of this study was to identify findings on MRE 46 weeks after initiating biological treatment that predict adverse long-term outcomes. METHODS: Patients with CD underwent MRE 46 weeks after initiating biological treatment and were prospectively followed for 2 years...
April 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38649335/steatotic-liver-disease-associated-all-cause-cause-specific-mortality-in-the-united-states
#36
JOURNAL ARTICLE
Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
BACKGROUND: Recently, a panel of multi-society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction-associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD). AIMS: We compared the impact of SLD, subtype of SLD, MAFLD and NAFLD on all-cause and cause-specific mortality. METHODS: A total of 7811 individuals in the third National Health and Nutrition Examination Survey and linked mortality through 2019 were analysed...
April 22, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38644588/randomised-clinical-trial-first-line-infliximab-biosimilar-is-cost-effective-compared-to-conventional-treatment-in-paediatric-crohn-s-disease
#37
JOURNAL ARTICLE
Stephanie A Vuijk, Maria M E Jongsma, Britt M Hoeven, Maarten A Cozijnsen, Merel van Pieterson, Tim G J de Meij, Obbe F Norbruis, Michael Groeneweg, Victorien M Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick F van Rheenen, Michiel P van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J Poley, Johanna C Escher, Lissy de Ridder
BACKGROUND: Data on cost-effectiveness of first-line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed. AIM: To investigate the cost-effectiveness of first-line infliximab compared to conventional treatment in children with moderate-to-severe Crohn's disease. METHODS: We included patients from the Top-down Infliximab Study in Kids with Crohn's disease randomised controlled trial...
April 21, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38643507/editorial-peering-through-the-fog-new-tools-to-assess-neurocognitive-symptoms-in-coeliac-disease
#38
EDITORIAL
Javier A Villafuerte Gálvez, Daniel A Leffler
No abstract text is available yet for this article.
April 21, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38643506/editorial-are-changes-in-quantitative-biliary-metrics-the-first-sign-of-progression-in-primary-sclerosing-cholangitis
#39
EDITORIAL
John E Eaton, Sudhakar K Venkatesh
No abstract text is available yet for this article.
April 21, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38643505/letter-presence-of-progression-or-absence-of-response-alternative-trial-designs-for-immunotherapy-of-advanced-hepatocellular-carcinoma
#40
LETTER
Enrico N De Toni, Julia Mayerle, Bettina Oehrle, Max Seidensticker, Lorenza Rimassa, Alexander Philipp, Daniel Roessler, Najib Ben Khaled
No abstract text is available yet for this article.
April 21, 2024: Alimentary Pharmacology & Therapeutics
journal
journal
29552
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.